Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has received acceptance for its IPO on the Shenzhen Stock Exchange's ChiNext board, aiming to raise 1.7 billion RMB for its operations in the high-performance vascular interventional medical device sector [1]. Group 1: Company Overview - Boma Medical specializes in the research, production, and global sales of high-performance vascular interventional medical devices, positioning itself as a leading provider of complex vascular disease intervention solutions [1]. - The company has developed a comprehensive product matrix with over 50 product series, covering critical areas such as coronary intervention, peripheral intervention, neurointervention, blood dialysis pathways, and interventional accessories [1]. Group 2: Market Presence - Boma Medical's products are marketed in over 100 countries and regions, serving thousands of hospitals and medical centers globally, establishing a strong brand image in the vascular interventional medical device market [2]. - The company has maintained a stable and rapid growth trajectory in both domestic and international markets, with a projected compound annual growth rate (CAGR) of 48.98% in revenue from 2022 to 2024 [2]. Group 3: Financial Performance - In terms of market share, Boma Medical is projected to hold 9.6% of the coronary balloon dilation catheter market in China, ranking fourth overall and first among domestic brands, and 4.7% of the peripheral artery balloon dilation catheter market, ranking fifth [3]. - The company reported revenues of approximately 207 million RMB, 335 million RMB, 460 million RMB, and 303 million RMB for the years 2022, 2023, 2024, and the first half of 2025, respectively, with net profits showing a significant turnaround from a loss of 36 million RMB in 2022 to a profit of 35.6 million RMB in the first half of 2025 [3][4]. Group 4: Fundraising and Investment Plans - The funds raised from the IPO will be allocated to various projects, including the establishment of a global headquarters, production base upgrades, and research and development for interventional medical devices, with a total planned investment of approximately 1.814 billion RMB [3].